Page last updated: 2024-11-07

2-palmitoylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-palmitoylglycerol: increases 2-arachidonoyl-glycerol cannabinoid activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-palmitoylglycerol : A 2-monoglyceride where the acyl group is hexadecanoyl (palmitoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123409
CHEMBL ID1317070
CHEBI ID75455
SCHEMBL ID133614
MeSH IDM0296223

Synonyms (58)

Synonym
palmitin, 2-mono-
hexadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester
2-monohexadecanoylglycerol
NCGC00092337-01
P-1120
2-monopalmitin
1,3-dihydroxypropan-2-yl hexadecanoate
2-palmitoylglycerol
hexadecanoic acid 2-hydroxy-1-(hydroxymethyl)ethyl ester
23470-00-0
2-palmitoyl-glycerol
mg(0:0/16:0/0:0)
2-hexadecanoyl-sn-glycerol
LMGL01010025
hexadecanoic acid,2-hydroxy-1-(hydroxymethyl)ethyl ester
QSPL 170
2-hexadecanoylglycerol
mg (0:0/16:0/0:0)
2-o-palmitoylglycerol
1,3-dihydroxypropan-2-yl palmitate
AKOS015951327
CHEMBL1317070
chebi:75455 ,
FT-0673488
2-hexadecanoyl glycerol
glycerol, 2-palmitate
palmitin, 2-mono
unii-21i29v2935
2-monopalmitoyl-sn-glycerol
beta-monopalmitin
21i29v2935 ,
2-monopalmitoylglycerol
glyceryl 2-hexadecanoate
glyceryl 2-palmitate
.beta.-monopalmitin
SCHEMBL133614
bdbm197166
2-palmitoylmonoglycerol (2-pg)
2-palm-gl
2-hydroxy-1-(hydroxymethyl)ethyl hexadecanoic acid ester
glycerol .beta.-palmitate
palmitic acid .beta.-monoglyceride
glycerol 2-hexadecanoate
2-hydroxy-1-(hydroxymethyl)ethyl palmitate
BBNYCLAREVXOSG-UHFFFAOYSA-N
DTXSID30178024
2-palmitoylglycerol, analytical standard
J-015121
mag(0:0/16:0)
2-hexadecanoyl-rac-glycerol
mg(0:0/16:0)
Q27145323
1,3-dihydroxypropan-2-ylpalmitate
VLP ,
MS-24972
CS-W014504
HY-W013788
PD017581
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-acylglycerol 16:0A 2-monoglyceride in which the acyl group contains 16 carbons and is fully saturated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (148)

PathwayProteinsCompounds
Glycerolipid Metabolism1124
Glycerol Kinase Deficiency1124
D-Glyceric Acidura1124
Familial Lipoprotein Lipase Deficiency1124
Triacylglycerol Degradation TG(16:0/16:0/16:0)511
Triacylglycerol Degradation TG(16:0/16:0/18:0)512
Triacylglycerol Degradation TG(16:0/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(16:0/16:0/20:0)512
Triacylglycerol Degradation TG(16:0/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(16:0/16:0/20:1(13Z))511
Triacylglycerol Degradation TG(16:0/16:0/22:0)512
Triacylglycerol Degradation TG(16:0/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:0/16:0/16:0)511
Triacylglycerol Degradation TG(18:0/16:0/18:0)512
Triacylglycerol Degradation TG(18:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/16:0/20:0)513
Triacylglycerol Degradation TG(18:0/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/16:0/22:0)513
Triacylglycerol Degradation TG(18:0/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(20:0/16:0/16:0)511
Triacylglycerol Degradation TG(20:0/16:0/18:0)513
Triacylglycerol Degradation TG(20:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/16:0/20:0)512
Triacylglycerol Degradation TG(20:0/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/16:0/22:0)513
Triacylglycerol Degradation TG(20:0/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/16:0)511
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(13Z)/16:0/16:0)510
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/16:0/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/22:1(13Z))511
Triacylglycerol Degradation TG(22:0/16:0/16:0)512
Triacylglycerol Degradation TG(22:0/16:0/18:0)513
Triacylglycerol Degradation TG(22:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/16:0/20:0)513
Triacylglycerol Degradation TG(22:0/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/16:0/22:0)512
Triacylglycerol Degradation TG(22:0/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/16:0)511
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/22:1(13Z))512

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency6.30960.002014.677939.8107AID1476
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
mitogen-activated protein kinase 1Homo sapiens (human)Potency12.58930.039816.784239.8107AID1454
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency15.84890.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, liverMus musculus (house mouse)Ki0.07000.02100.34832.0000AID1802031
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID681134TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells2004British journal of pharmacology, Oct, Volume: 143, Issue:3
Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.
AID1802031FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's2 (14.29)29.6817
2010's5 (35.71)24.3611
2020's6 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.07 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index31.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]